TCGA-CV-7089-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.450228311
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- MYC_TARGETS_V2+0.430
- INTERFERON_GAMMA_RESPONSE+0.390
- MYC_TARGETS_V1+0.340
- G2M_CHECKPOINT+0.310
- ESTROGEN_RESPONSE_EARLY+0.280
- APICAL_SURFACE+0.260
- E2F_TARGETS+0.250
- P53_PATHWAY+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
Top 10 suppressed
- ANGIOGENESIS-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- MYOGENESIS-0.300
- UV_RESPONSE_DN-0.130
- NOTCH_SIGNALING-0.090
- BILE_ACID_METABOLISM-0.080
- CHOLESTEROL_HOMEOSTASIS-0.080
- WNT_BETA_CATENIN_SIGNALING-0.070
- PANCREAS_BETA_CELLS-0.060
- KRAS_SIGNALING_UP-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.855 |
| 2 | TCGA-MT-A51W-01A-21R-A266-07 | — | — | 0.846 |
| 3 | TCGA-D6-6516-01A-11R-1873-07 | — | — | 0.833 |
| 4 | SRR15069615 | — | — | 0.832 |
| 5 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.828 |
| 6 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.815 |
| 7 | TCGA-CV-7099-01A-41R-2016-07 | — | — | 0.806 |
| 8 | ERR2278877 | — | — | 0.806 |
| 9 | ERR2278859 | — | — | 0.802 |
| 10 | ERR2278873 | — | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |